Merck (MRK) tops Q3 expectations on sustained growth in oncology and vaccine segments
Tweet Send to a Friend
Merck (NYSE: MRK) reported earnings before the open Thursday, topping both profit and revenue consensus expectations. The pharmaceutical company reported ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


